Heartbeam Inc (BEAT)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $25.04M
Last updated: Nov 17, 2026 at 11:05 AM ET
Heartbeam Inc (BEAT) Earnings: Report Dates and Results
Heartbeam (BEAT) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Heartbeam reported EPS of -$0.05, above the -$0.09 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
BEAT has an expected report date of Mar 10, 2027.
BEAT Earnings Call
The latest BEAT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 37 quarters below that had an estimate, BEAT beat 18, missed 13 and matched 6. The widest gap in the table came in the quarter ended Dec 31, 2024, when EPS landed 329.41% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.05 | -$0.09 | -$0.10 - -$0.08 | +44.44% | Beat | N/A | 3 | 1 up, 0 down | Nov 12, 2026 | N/A |
| Jun 30, 2026 | -$0.10 | -$0.10 | -$0.11 - -$0.08 | 0.00% | In line | N/A | 4 | 3 up, 0 down | Aug 13, 2026 | N/A |
| Mar 31, 2026 | -$0.12 | -$0.13 | -$0.14 - -$0.13 | +7.69% | Beat | N/A | 4 | 1 up, 1 down | May 13, 2026 | N/A |
| Dec 31, 2025 | -$0.14 | -$0.16 | -$0.16 - -$0.10 | +9.68% | Beat | N/A | 4 | 1 up, 0 down | Mar 12, 2026 | N/A |
| Sep 30, 2025 | -$0.15 | -$0.15 | -$0.16 - -$0.15 | 0.00% | In line | N/A | 2 | 1 up, 0 down | Nov 13, 2025 | N/A |
| Jun 30, 2025 | -$0.15 | -$0.16 | N/A | +6.25% | Beat | N/A | N/A | 0 up, 0 down | Aug 13, 2025 | N/A |
| Mar 31, 2025 | -$0.18 | -$0.15 | N/A | -20.00% | Miss | N/A | N/A | 0 up, 0 down | May 13, 2025 | N/A |
| Dec 31, 2024 | -$0.73 | -$0.17 | N/A | -329.41% | Miss | N/A | N/A | 0 up, 0 down | Mar 13, 2025 | N/A |
| Sep 30, 2024 | -$0.19 | -$0.17 | -$0.18 - -$0.17 | -11.76% | Miss | N/A | 2 | 0 up, 0 down | Nov 7, 2024 | N/A |
| Jun 30, 2024 | -$0.19 | -$0.16 | -$0.18 - -$0.15 | -18.75% | Miss | N/A | 2 | 0 up, 0 down | Aug 14, 2024 | N/A |
| Mar 31, 2024 | -$0.17 | -$0.15 | -$0.15 - -$0.15 | -13.33% | Miss | N/A | 1 | 0 up, 0 down | May 9, 2024 | N/A |
| Dec 31, 2023 | -$0.15 | -$0.13 | -$0.14 - -$0.12 | -15.38% | Miss | N/A | 4 | 0 up, 0 down | Mar 20, 2024 | N/A |
| Sep 30, 2023 | -$0.13 | -$0.13 | -$0.13 - -$0.13 | 0.00% | In line | N/A | 3 | 0 up, 0 down | Nov 14, 2023 | N/A |
| Jun 30, 2023 | -$0.16 | -$0.20 | N/A | +20.00% | Beat | N/A | 2 | 0 up, 0 down | Aug 10, 2023 | N/A |
| Mar 31, 2023 | -$0.50 | -$0.33 | -$0.44 - -$0.18 | -51.52% | Miss | N/A | 2 | 0 up, 0 down | May 11, 2023 | N/A |
| Dec 31, 2022 | -$0.45 | -$0.37 | -$0.48 - -$0.17 | -21.62% | Miss | N/A | 3 | 0 up, 0 down | Mar 16, 2023 | N/A |
| Sep 30, 2022 | -$0.44 | -$0.34 | -$0.34 - -$0.31 | -29.41% | Miss | N/A | 2 | 0 up, 0 down | Nov 10, 2022 | N/A |
| Jun 30, 2022 | -$0.43 | -$0.27 | -$0.27 - -$0.27 | -59.26% | Miss | N/A | 1 | 0 up, 0 down | Aug 11, 2022 | N/A |
| Mar 31, 2022 | -$0.27 | -$0.19 | -$0.19 - -$0.19 | -42.11% | Miss | N/A | 1 | 0 up, 0 down | May 12, 2022 | N/A |
| Dec 31, 2021 | -$0.24 | -$0.11 | N/A | -118.18% | Miss | N/A | N/A | 0 up, 0 down | Mar 24, 2022 | N/A |
| Sep 30, 2021 | -$0.32 | -$0.32 | N/A | 0.00% | In line | -171.1% | N/A | N/A | Nov 17, 2021 | N/A |
| Jun 30, 2021 | -$0.02 | N/A | N/A | N/A | N/A | -105.7% | N/A | N/A | Jul 9, 2021 | N/A |
| Mar 31, 2021 | -$0.26 | N/A | N/A | N/A | N/A | -156.8% | N/A | N/A | Jun 30, 2021 | N/A |
| Dec 31, 2020 | -$0.06 | N/A | N/A | N/A | N/A | -111.9% | N/A | N/A | Feb 22, 2021 | N/A |
| Sep 30, 2020 | $0.45 | $0.38 | N/A | +18.42% | Beat | -13.5% | N/A | N/A | Oct 29, 2020 | N/A |
| Jun 30, 2020 | $0.35 | $0.16 | N/A | +118.75% | Beat | -34.0% | N/A | N/A | Jul 30, 2020 | $99.11M |
| Mar 31, 2020 | $0.45 | $0.43 | N/A | +4.65% | Beat | +7.1% | N/A | N/A | May 6, 2020 | $113.03M |
| Dec 31, 2019 | $0.48 | $0.48 | N/A | 0.00% | In line | -14.3% | N/A | N/A | Feb 26, 2020 | $112.03M |
| Sep 30, 2019 | $0.52 | $0.50 | N/A | +4.00% | Beat | -1.9% | N/A | N/A | Nov 5, 2019 | $111.29M |
| Jun 30, 2019 | $0.53 | $0.45 | N/A | +17.78% | Beat | +15.2% | N/A | N/A | Jul 30, 2019 | $111.80M |
| Mar 31, 2019 | $0.42 | $0.41 | N/A | +2.44% | Beat | +7.7% | N/A | N/A | Apr 25, 2019 | $103.98M |
| Dec 31, 2018 | $0.56 | $0.43 | N/A | +30.23% | Beat | +75.0% | N/A | N/A | Feb 21, 2019 | $103.60M |
| Sep 30, 2018 | $0.53 | $0.32 | N/A | +65.63% | Beat | +231.3% | N/A | N/A | Oct 30, 2018 | $100.01M |
| Jun 30, 2018 | $0.46 | $0.31 | N/A | +48.39% | Beat | +100.0% | N/A | N/A | Jul 25, 2018 | $101.36M |
| Mar 31, 2018 | $0.39 | $0.23 | N/A | +69.57% | Beat | +143.8% | N/A | N/A | Apr 25, 2018 | $94.50M |
| Dec 31, 2017 | $0.32 | $0.24 | N/A | +33.33% | Beat | +39.1% | N/A | N/A | Feb 22, 2018 | $91.74M |
| Sep 30, 2017 | $0.16 | $0.25 | N/A | -36.00% | Miss | -23.8% | N/A | N/A | Nov 7, 2017 | $81.02M |
| Jun 30, 2017 | $0.23 | $0.21 | N/A | +9.52% | Beat | +15.0% | N/A | N/A | Aug 8, 2017 | $58.13M |
| Mar 31, 2017 | $0.16 | $0.16 | N/A | 0.00% | In line | -20.0% | N/A | N/A | May 3, 2017 | $55.88M |
| Dec 31, 2016 | $0.23 | $0.18 | N/A | +27.78% | Beat | +53.3% | N/A | N/A | Feb 22, 2017 | $53.96M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.62, after -$1.28 the year before. It was $0.84 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.62 | N/A |
| Dec 31, 2024 | -$1.28 | N/A |
| Dec 31, 2023 | -$0.94 | N/A |
| Dec 31, 2022 | -$1.59 | N/A |
| Dec 31, 2021 | -$0.84 | -170.0% |
| Dec 31, 2020 | $1.19 | -38.8% |
| Dec 31, 2019 | $1.95 | N/A |
| Dec 31, 2018 | $1.94 | +123.0% |
| Dec 31, 2017 | $0.87 | N/A |
| Dec 31, 2016 | $0.84 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,800 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,816 | 7 | |
| 2026Q2 | Jun 30, 2026 | 7,648 | 8 | |
| 2026Q1 | Mar 31, 2026 | 6,701 | 7 | |
| 2025Q4 | Dec 31, 2025 | 8,774 | 9 | |
| 2025Q3 | Sep 30, 2025 | 5,066 | 6 | |
| 2025Q2 | Jun 30, 2025 | 5,444 | 5 | |
| 2025Q1 | Mar 31, 2025 | 5,724 | 6 | |
| 2024Q4 | Dec 31, 2024 | 4,797 | 3 |
2026Q3 Earnings Call
Opening remarks
Richard Ferrari Executive Chairman Thank you, and thanks to all of you who have dialed into the conference call. Let me just walk you through the agenda very briefly. We're going to give you the progress on our key strategic initiatives. We'll bring you updates regarding our cardiac platform and our heart attack detection, which is an incredible milestone that we've achieved this particular quarter. And then finally, we'll close out with the financials. Next slide. The progress on the key strategic priorities. I think many of you who have been following the company will remember that in July of this year, we outlined our plan going forward, and we organized the focus on our core strategic priorities, which are shown on this particular slide. That was MI detection, working closely with the FDA, working on reimbursement, enhancing the long-term value of the company through AI and the other technological initiatives, and then on the financial side, cost efficiency and tight controls with respect to running the company. Now, when you look at heart attack detection, I have to say that in the last 90 days, Q3 was a fabulous quarter for achievement, and I think that's a testament to the team we have and the shift to the priorities that I have already mentioned. When you look at those achievements, these milestones are, for a small company, quite significant. Getting Breakthrough Device Designation, something we were really going after and really wanted to count on. And just to give you sort of a reference point, the FDA, on average over the last 5, 6, 7 years, only hands out about 164 of these designations. So it's proof that the technology and the opportunity to enhance patients' lives is significant with respect to HeartBeam. That also enabled us to get enrolled, if you will, into their TAP program. Now, the TAP program is also quite significant because it enables us to have faster turnaround with our communications with the FDA. It also opens up CMS and payers so that we can have discussions with them regarding reimbursement and what needs they need to see in our clinical trial to establish reimbursement. And then I think many of you may know that we had our publication, our presentation at the TCT meeting at the end of October, which again, in our perspective, is the first study—it was 132 patients—to really look at, in an emergency room setting, a comparison between the gold standard of the last 50 years, the 12-lead EKG, and our handheld device for MI detection. And those results, Branislav will touch on a little bit later in this presentation, were significant. I don't know that we've said this before.
Frequently Asked Questions About BEAT
When is Heartbeam's next earnings date?
Heartbeam's next earnings report is expected for Mar 10, 2027.
Did BEAT beat earnings estimates last quarter?
Yes. Heartbeam reported EPS of -$0.05 for the quarter ended Sep 30, 2026, above the -$0.09 estimate, a 44.44% surprise.
What EPS do analysts expect from BEAT next quarter?
The consensus EPS estimate for Heartbeam for the quarter ending Dec 31, 2026 is -$0.09 from 5 analysts, with estimates from -$0.10 to -$0.08.
How often does BEAT beat earnings estimates?
Heartbeam beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -35.17%.
BEAT pages: Overview, Earnings, Forecast, Financials, Competitors